Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer

Human NSCLCs with activating mutations in EGFR frequently respond to treatment with EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib but responses are not durable as tumors acquire resistance. Secondary mutations in EGFR (T790M) or upregulation of the MET kinase are found in over 50% of resi...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhang, Zhenfeng, Lee, Jae Cheol, Lin, Luping, Olivas, Victor, Au, Valerie, LaFramboise, Thomas, Abdel-Rahman, Mohamed, Wang, Xiaoqi, Levine, Alan D., Rho, Jin Kyung, Choi, Yun Jung, Choi, Chang-Min, Kim, Sang-We, Jang, Se Jin, Park, Young Soo, Kim, Woo Sung, Lee, Dae Ho, Lee, Jung-Shin, Miller, Vincent A., Arcila, Maria, Ladanyi, Marc, Moonsamy, Philicia, Sawyers, Charles, Boggon, Titus J., Ma, Patrick C., Costa, Carlota, Taron, Miquel, Rosell, Rafael, Halmos, Balazs, Bivona, Trever G.
Format: Artigo
Language:Inglês
Published: 2012
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3408577/
https://ncbi.nlm.nih.gov/pubmed/22751098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ng.2330
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items